Management of CAD-RADS 1 with LVEF 73.5%
For a patient with CAD-RADS 1 (minimal coronary disease with 1-24% stenosis) and preserved left ventricular function (LVEF 73.5%), no further cardiac testing or invasive evaluation is needed—focus exclusively on outpatient risk factor modification and preventive pharmacotherapy. 1
Clinical Approach
Immediate Management
- No hospital admission required - CAD-RADS 1 represents minimal, non-obstructive coronary disease that does not warrant acute intervention
- No stress testing or functional assessment needed - The degree of stenosis is too minimal to cause flow-limiting ischemia
- No invasive coronary angiography - ICA rates for CAD-RADS 0-2 should be approximately 13%, and only in specific clinical contexts 2
The LVEF of 73.5% Context
The supranormal ejection fraction (73.5%) is reassuring and indicates:
- No ventricular dysfunction from coronary disease
- No indication for revascularization based on ventricular function (revascularization for prognostic benefit requires functionally significant stenosis, which CAD-RADS 1 does not represent) 3
- The slightly elevated LVEF may reflect hyperdynamic circulation, hypertension, or measurement variability, but does not change management for minimal CAD
Outpatient Management Strategy
Risk Factor Modification (Aggressive Approach)
According to CAD-RADS 2.0 guidelines, the presence of any atherosclerotic plaque (even 1-24% stenosis) warrants aggressive preventive measures 1:
Lipid Management:
- High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily)
- Target LDL-C <70 mg/dL, consider <55 mg/dL for very high-risk features
- Add ezetimibe if LDL target not achieved with statin alone
Blood Pressure Control:
- Target <130/80 mmHg
- ACE inhibitor or ARB preferred if hypertensive or diabetic
Antiplatelet Therapy:
- Aspirin 81 mg daily for secondary prevention (patient has documented atherosclerosis)
Diabetes Management (if present):
- HbA1c target <7%
- Consider SGLT2 inhibitor or GLP-1 agonist with cardiovascular benefit
Lifestyle Modifications:
- Mediterranean diet or DASH diet
- Minimum 150 minutes moderate-intensity aerobic exercise weekly
- Smoking cessation if applicable
- Weight management (BMI <25 kg/m²)
Follow-up Surveillance
- No routine repeat coronary CTA indicated unless new symptoms develop
- Annual cardiovascular risk assessment
- Monitor adherence to preventive medications and lifestyle changes
- Serial lipid panels every 3-6 months until at goal, then annually
Critical Pitfalls to Avoid
Do not over-investigate: CAD-RADS 1 patients frequently undergo unnecessary invasive procedures. Research shows 13% of CAD-RADS 0-2 patients received ICA, many without appropriate indication 2. This patient needs medical management, not catheterization.
Do not dismiss the plaque burden: Even minimal stenosis represents atherosclerotic disease requiring aggressive risk modification. The presence of any plaque (P1-P4 modifier in CAD-RADS 2.0) should intensify preventive efforts 1.
Do not attribute symptoms to CAD-RADS 1 lesions: If the patient has chest pain, 1-24% stenosis cannot explain angina. Consider other etiologies (microvascular disease, non-cardiac causes) rather than pursuing revascularization.
Avoid complacency with "normal" EF: While the LVEF is preserved, this doesn't negate the need for aggressive atherosclerosis management to prevent disease progression.
Prognostic Context
CAD-RADS 1 carries excellent 5-year prognosis with 95.2% event-free survival when managed appropriately 2. The standardized reporting system effectively stratifies risk, with CAD-RADS 1 representing low-risk disease that responds well to medical therapy alone. The preserved LVEF further supports excellent prognosis with appropriate preventive care.